Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Trial Status: Active
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of giving an oral targeted FGFR1-3 inhibitor, infigratinib, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations [ie, rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and / or nephrectomy. Study treatment is randomized between infigratinib or placebo with treatment until invasive local or distal disease recurrence.
- Have histologically or cytologically confirmed, invasive urothelial carcinoma with susceptible FGFR3 alterations within 120 days following nephroureterectomy, distal ureterectomy, or cystectomy
- If the patient received neoadjuvant chemotherapy, pathologic stage at surgical resection must be AJCC Stage ≥ ypT2 and/or yN+.
- If the patient did not receive neoadjuvant chemotherapy:
- Must be ineligible to receive cisplatin-based adjuvant chemotherapy per the Galsky criteria:
- creatinine clearance < 60cc/min or
- ≥ Grade 2 hearing loss or
- ≥ Grade 2 neuropathy)
- Pathologic stage must be AJCC Stage ≥pT2 pN0-2 M0 (post-lymphadenectomy or no lymphadenectomy [pNx]) for upper tract disease.
- Pathologic stage should be AJCC Stage ≥pT3 or pN+ (bladder cancer).
- Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
- Patients must have no evidence of metastatic disease based on screening CT or MRI.
- Presence of positive surgical margins following nephroureterectomy, distal ureterectomy, or cystectomy.
- Have received Bacillus Calmette-Guerin (BCG) or other intravesical therapy for Non-Muscle Invasive Bladder Cancer (NMIBC) within the previous 30 days.
- Have previously or currently is receiving treatment with a mitogen-activated protein kinase (MEK) or selective FGFR inhibitor.
- Have impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (eg, active ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)
- Have current evidence of corneal or retinal disorder/keratopathy.
- Have a history and/or current evidence of extensive tissue calcification.
- Have current evidence of endocrine alterations of calcium/phosphate homeostasis (eg, parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis), unless well controlled.
- Are currently receiving or are planning to receive during participation in this study, treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration.
- Clinically significant cardiac disease.
- Recent (< 3 months prior to first dose of study drug) transient ischemic attack or stroke.
University of Alabama at Birmingham Cancer Center
Contact: Arnab Basu
City of Hope Comprehensive Cancer Center
Los Angeles County-USC Medical Center
Contact: Cheryl Kefauver
USC / Norris Comprehensive Cancer Center
Contact: Cheryl Kefauver
USC Norris Oncology / Hematology-Newport Beach
Contact: Kristy Marie Massopust
University of California Davis Comprehensive Cancer Center
University of Colorado Hospital
Emory University Hospital / Winship Cancer Institute
University of Chicago Comprehensive Cancer Center
Indiana University / Melvin and Bren Simon Cancer Center
Contact: Miranda Wineland
Johns Hopkins University / Sidney Kimmel Cancer Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Dartmouth Hitchcock Medical Center
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
University of Oklahoma Health Sciences Center
UT Southwestern / Simmons Cancer Center-Dallas
Contact: Marcella West Aguilar
M D Anderson Cancer Center
Salt Lake City
Huntsman Cancer Institute / University of Utah
Fred Hutch / University of Washington Cancer Consortium
Trial Phase Phase III
Trial Type Treatment
QED Therapeutics, Inc.
- Primary ID QBGJ398-302
- Secondary IDs NCI-2020-00610, 2019-003248-63
- Clinicaltrials.gov ID NCT04197986